Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | E586K |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | BRAF E586K (also reported as E585K) lies within the protein kinase domain of the Braf protein (UniProt.org). E586K results in increased Braf kinase activity, and activation of Mek and Erk in cell culture (PMID: 15035987, PMID: 22510884), increases cell proliferation and viability compared to wild-type Braf in one of two cell lines (PMID: 29533785), and is associated with EGFR inhibitor resistance in the context of an EGFR exon 19 deletion and Braf V590I, G593V, and D594N (PMID: 38838224). |
| Associated Drug Resistance | |
| Category Variants Paths |
BRAF mutant BRAF act mut BRAF E586K BRAF mutant BRAF E586X BRAF E586K |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140753379C>T |
| cDNA | c.1756G>A |
| Protein | p.E586K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001378474.1 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_001378468.1 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_004333 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_001378471.1 | chr7:g.140749412C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_001354609.1 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| XM_005250045 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_004333.5 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| NM_001354609.2 | chr7:g.140753379C>T | c.1756G>A | p.E586K | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |